Skip to main content

Table 1 Characteristics of 61 patients with antiphospholipid syndrome and 146 controls enrolled in the study

From: Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers

  Number Median age, years Age range, years Gender f/m
PAPS* 34 46 21–75 23/11
 arterial thrombosis 23 47 21–66 15/8
 venous thrombosis 12 42 28–63 8/4
 thrombotic and obstetric manifestations 5 41 33–51 5/0
OAPSa 22 39 27–62 22/0
 early pregnancy loss (<10th week of gestation) 11 38 34–45 11/0
 intrauterine death (>10th week of gestation) 14 40 27–57 14/0
 premature birth 5 37 33–42 5/0
 fetuses with intrauterine growth retardation 9 35 27–42 9/0
 pre/eclampsia 6 34 27–37 6/0
SAPSb 5 38 24–58 4/1
aPL+ 24 42 22–71 22/2
IDC 50 35 6–86 46/4
VDRL+ 23 36 19–58 2/21
HS 49 37 19–68 9/40
  1. PAPS primary antiphospholipid syndrome, OAPS obstetric primary antiphospholipid syndrome, HS healthy subjects, aPL+, anti-phospholipid antibody positive, IDC infectious diseases controls, VDRL+ Venereal Disease Research Laboratory test positive, f female, m male. aPatients with PAPS or OAPS may have more than one of the indicated clinical manifestations. bSecondary antiphospholipid syndrome (SAPS): three were associated with systemic lupus erythematosus, two out of three with arterial thrombosis and one with arterial thrombosis and intrauterine death; two were associated with undifferentiated connective tissue disease and with intrauterine deaths